2025年4月18日 星期五
首页        期刊介绍        编委会        投稿指南        期刊订阅        广告合作        联系我们        English
河北医学  2021, Vol. 27 Issue (2): 254-259    DOI: 10.3969/j.issn.1006-6233.2021.02.017
  临床研究 本期目录 | 过刊浏览 | 高级检索 |
急性冠脉综合征患者血清中白细胞介素-10 CXC趋化因子16水平变化及其意义
马伟利, 蔡颖, 宝凤梅, 张凤梅, 张莉莉
辽宁省朝阳市中心医院心内科, 辽宁 朝阳 122000
Levels of Serum IL-10, CXCL16 in Patients with Acute Coronary Syndrome and Its Clinical Significance
MA Weili, CAI Ying, BAO Fengmei, et al
Chaoyang Central Hospital, Liaoning Chaoyang 122000, China
全文: PDF (1267 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的: 探讨急性冠脉综合征(ACS)患者血清白细胞介素-10(IL-10)、CXC趋化因子16(CXCL16)水平及其临床意义。方法: 选取2017年6月至2019年6月我院收治的150例ACS患者为研究对象(ACS组),根据疾病类型分为急性心肌梗死组(AMI组,n=79)和不稳定性心绞痛组(UAP,n=71),根据Gensini积分分为轻度病变组(n=65)、中度病变组(n=52)、重度病变组(n=33),根据冠状动脉病变支数分为单支病变组(n=60)、双支病变组(n=58)、3支病变组(n=32)。并于同期随机选取60例稳定性心绞痛患者(SAP组)和60例健康体检者(对照组)为对照。采用酶联免疫吸附法检测血清IL-10、CXCL16水平。结果: ACS组血清IL-10、CXCL16水平高于SAP组和对照组(P<0.05)。AMI组血清IL-10、CXCL16水平高于UAP组,差异有统计学意义(t=9.186、6.643,P<0.05)。随着ACS组患者冠脉病变程度加重和冠脉病变支数增加,血清IL-10、CXCL16水平逐渐升高(P<0.05)。ACS组患者血清IL-10与Gensini积分、冠脉病变支数呈正相关性(r=0.692、0.702,P<0.05),CXCL16与Gensini积分、冠脉病变支数呈正相关性(r=0.637、0.645,P<0.05)。ROC曲线分析结果显示IL-10、CXCL16对AMI、UAP均有鉴别诊断价值,且两指标联合检测的鉴别诊断价值较高,AUC为0.860(95%CI:0.835~0.907),灵敏度和特异性分别为89.67%、82.39%,准确性为86.34%。结论: 血清IL-10、CXCL16表达上调参与了ACS发病过程,并且与冠脉病变Gensini积分和冠脉病变支数密切相关,早期联合检测可作为临床辅助鉴别诊断ACS及评估冠脉病变严重程度的重要生化指标。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 急性冠脉综合征白细胞介素-10CXC趋化因子16    
AbstractObjective: To explore the levels of serum interleukin-10 (IL-10) and CXC chemokine ligand 16 (CXCL16) in patients with acute coronary syndrome (ACS) and its clinical significance. Methods: A total of 150 patients with ACS admitted to our hospital from June 2018 to June 2019 were selected as study objects (ACS group), who were divided into acute myocardial infarction group (AMI group, n=79) and unstable angina pectoris group (UAP group, n=71) according to the disease type. Also, the patients were divided into mild lesion group (n=65), moderate lesion group (n=52) and severe group (n=33) according to Gensini score. And the patients were divided into single vessel lesion group (n=60), double vessel lesion group (n=58) and triple vessel lesion group (n=32) according to the number of coronary artery lesions. At the same time, 60 patients with stable angina pectoris (SAP group) and 60 healthy volunteers (control group) were randomly selected as controls. The serum IL-10 and CXCL16 levels were detected by enzyme-linked immunosorbent assay. Results: The levels of IL-10 and CXCL16 in ACS group were higher than those in SAP group and control group (P<0.05). The level of IL-10 and CXCL16 in AMI group were higher than those in UAP group (t=9.186, 6.643; P<0.05). With the severity and number of coronary lesions in ACS group, the IL-10 and CXCL16 increased (P<0.05). The serum IL-10 in ACS group was positively associated with the Gensini scores and the number of coronary lesions (r=0.692, 0.702; P<0.05), and the CXCL16 was positively associated with the Gensini scores and the number of coronary lesions (r=0.637, 0.645; P<0.05). The ROC curve analysis showed that IL-10 and CXCL16 have differential diagnostic value for AMI and UAP, and the combined detection of both IL-10 and CXCL16 have a higher differential diagnostic value. The AUC was 0.860 (95%CI: 0.835~0.907), the sensitivity and specificity were 89.67% and 82.39%, and the accuracy was 86.34%. Conclusion: The up-regulation of serum IL-10 and CXCL16 are involved in the pathogenesis of ACS, which are closely related to the Gensini score of coronary lesions and the number of coronary lesions. Early detection of both IL-10 and CXCL16 can be used as important biochemical indexes for clinical differential diagnosis of ACS and assessment of the severity of coronary lesions.
Key wordsAcute coronary syndrome    Interleukin-10    CXC chemokine ligand 16
    
基金资助:辽宁省卫生计生委科研课题,(编号:201602216)
引用本文:   
马伟利, 蔡颖, 宝凤梅, 张凤梅, 张莉莉. 急性冠脉综合征患者血清中白细胞介素-10 CXC趋化因子16水平变化及其意义[J]. 河北医学, 2021, 27(2): 254-259.
MA Weili, CAI Ying, BAO Fengmei, et al. Levels of Serum IL-10, CXCL16 in Patients with Acute Coronary Syndrome and Its Clinical Significance. HeBei Med, 2021, 27(2): 254-259.
链接本文:  
http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.02.017     或     http://www.hbyxzzs.cn/CN/Y2021/V27/I2/254
冀ICP备2025106803号    冀公网安备13080202000786号
版权所有 © 2016 《河北医学》杂志社
本系统由北京玛格泰克科技发展有限公司设计开发